Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 5/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207233 | 0.95 | POLB (0.37) | POLBPLK1TACR1TNKSPARP1 | |
| SCHEMBL14609731 | 0.87 | POLB (0.48) | POLBTACR1KMT2A | |
| SCHEMBL5213932 | 0.86 | DPP4 (0.36) | POLBFGFR1PLK1TACR1KMT2A | |
| SCHEMBL14609744 | 0.86 | MKNK1 (0.39) | POLBTACR1TNKSPARP1PARP2 | |
| SCHEMBL5212400 | 0.85 | TACR1 (0.39) | POLBTACR1TNKSPARP1PARP2 | |
| Hydrochloric Acid SCHEMBL5207599 | 0.85 | MKNK1 (0.38) | POLBTACR1TNKSPARP1PARP2 | |
| SCHEMBL14610117 | 0.84 | PARP1 (0.38) | POLBPLK1TACR1TNKSPARP1 | |
| SCHEMBL5213389 | 0.84 | TNKS (0.38) | POLBTACR1TNKSPARP1PARP2 | |
| SCHEMBL5212004 | 0.84 | TACR1 (0.41) | BRD4POLBTACR1TNKSPARP1 | |
| SCHEMBL14609747 | 0.83 | MKNK1 (0.41) | PLK1TACR1TNKSPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | BRD4 1996/4885POLB 3507/4885FGFR1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.